Pedrazzoli, Eleonora http://orcid.org/0000-0002-8420-2587
Demozzi, Michele
Visentin, Elisabetta http://orcid.org/0000-0001-6586-4123
Ciciani, Matteo http://orcid.org/0000-0003-2045-5435
Bonuzzi, Ilaria http://orcid.org/0000-0003-3179-474X
Pezzè, Laura http://orcid.org/0000-0001-8924-0083
Lucchetta, Lorenzo
Maule, Giulia http://orcid.org/0000-0002-7770-5688
Amistadi, Simone http://orcid.org/0000-0002-1140-9165
Esposito, Federica http://orcid.org/0000-0002-8521-4627
Lupo, Mariangela
Miccio, Annarita http://orcid.org/0000-0002-3409-9665
Auricchio, Alberto http://orcid.org/0000-0002-0832-2472
Casini, Antonio http://orcid.org/0000-0001-7709-4955
Segata, Nicola http://orcid.org/0000-0002-1583-5794
Cereseto, Anna http://orcid.org/0000-0003-4453-2597
Article History
Received: 5 January 2024
Accepted: 11 April 2024
First Online: 24 April 2024
Competing interests
: The authors declare competing financial interests: A.Ce. is a co-founder and holds stocks of Alia Therapeutics, a genome editing company. A.Ca. is a co-founder, holds stocks and is currently an employee of Alia Therapeutics. L.P. is an employee of Alia Therapeutics. M.C. and N.S. are consultants of Alia Therapeutics. AA is co-founder and shareholder of InnovaVector. Pending patent applications (WO2023118349 and WO2024056880, claiming priority to USPTO applications) covering nucleases presented in this work have been filed by Alia Therapeutics. The remaining authors declare no competing interests.